| 17.12 1.44 (9.18%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.86 |
1-year : | 26.47 |
| Resists | First : | 19.57 |
Second : | 22.67 |
| Pivot price | 15.91 |
|||
| Supports | First : | 14.56 |
Second : | 12.11 |
| MAs | MA(5) : | 16.14 |
MA(20) : | 16.25 |
| MA(100) : | 14.71 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.2  |
| %K %D | K(14,3) : | 37.5 |
D(3) : | 23.4 |
| RSI | RSI(14): 58.2 |
|||
| 52-week | High : | 22.67 | Low : | 11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GENB ] has closed It is unclear right now based on current values. 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 17.85 - 17.92 | 17.92 - 17.98 |
| Low: | 15.86 - 15.94 | 15.94 - 16.01 |
| Close: | 16.97 - 17.11 | 17.11 - 17.23 |
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Wed, 16 Sep 2026
GENB: Generative AI-driven protein therapeutics advance with phase III asthma trials and novel oncology assets - TradingView
Tue, 08 Sep 2026
Generate Biomedicines to Present at Upcoming Investor Conferences - Quiver Quantitative
Tue, 01 Sep 2026
Frances Arnold plans 2026 stock sale in Generate Biomedicines (NASDAQ: GENB) - Stock Titan
Tue, 01 Sep 2026
Director at Generate Biomedicines (GENB) lines up a major stock sale - Stock Titan
Thu, 27 Aug 2026
Companies Like Generate Biomedicines (NASDAQ:GENB) Are In A Position To Invest In Growth - simplywall.st
Wed, 26 Aug 2026
Generate Biomedicines Stock Slides 20% as 103 Million Shares Clear Lock-Up - TechStock²
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 128 (M) |
| Held by Insiders | 6.045e+007 (%) |
| Held by Institutions | 14 (%) |
| Shares Short | 6,990 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.4955e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 134.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 2.648e+007 % |
| Gross Profit (p.s.) | -1.61 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -1.86 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -237 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 72.42 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 7.29e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|